Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical ABFRA:7UX 32 3-Year EBITDA Growth Rate is 50.30% as of Jun. 2026, which is 281% above its 10-year median of 13.20. GuruFocus rates FRA:7UX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Spago Nanomedical AB ranks better than 85.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 40.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 18.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Spago Nanomedical AB was 53.50% per year. The lowest was -25.80% per year. And the median was 13.20% per year.
Spago Nanomedical AB (FRA:7UX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Spago Nanomedical AB 3-Year EBITDA Growth Rate Related Terms
FRA:7UX vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's 3-Year EBITDA Growth Rate falls into.
Spago Nanomedical AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.30% mean?
Spago Nanomedical AB (FRA:7UX) has a 3-Year EBITDA Growth Rate of 50.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spago Nanomedical AB and its competitors. This is 281% above median its historical median of 13.20. According to the industry distribution chart, Spago Nanomedical AB ranks #159 out of 1127 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Spago Nanomedical AB's 3-Year EBITDA Growth Rate too high?
Spago Nanomedical AB's current 3-Year EBITDA Growth Rate of 50.30% is 281% above median its 10-year median of 13.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Spago Nanomedical AB's value of 50.30% is 244.5% above this industry median. Based on the distribution chart, Spago Nanomedical AB ranks #159 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spago Nanomedical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #159 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Spago Nanomedical AB in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Spago Nanomedical AB's value of 50.30% is 244.5% above this benchmark. While the company's 10-year median is 13.20 vs. the industry median of 14.60, Spago Nanomedical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spago Nanomedical AB's current 3-Year EBITDA Growth Rate of 50.30% is 244.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spago Nanomedical AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spago Nanomedical AB's current 3-Year EBITDA Growth Rate is 50.30%, which is 281% above median its own 10-year median of 13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current 3-Year EBITDA Growth Rate of 50.30%. The current 3-Year EBITDA Growth Rate is 50.30%, which is 281% above median its 10-year median of 13.20 and 244.5% above the Biotechnology industry median of 14.60. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current 3-Year EBITDA Growth Rate is 50.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score
Get the complete analysis for FRA:7UX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UX has been successfully added to your 
